Novel Dual‐acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients Results of 24 Week Treatment in a Phase III Monotherapy Trial (SEED Study)
Copyright ? 2026 Hua Medicine (Shanghai) Ltd. 沪网药械信备字【2026】000123号 沪ICP备14036654号-1沪公网安备 31011502013809号Privacy StatementTerms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.